Comparison of International Therapy Guidelines with Regard to the Treatment of Malignant Catatonia

Pharmacopsychiatry. 2020 Jan;53(1):14-20. doi: 10.1055/a-1007-1949. Epub 2019 Sep 26.

Abstract

Objective: Malignant catatonia (MC) is an extremely rare, life-threatening disorder. It is characterized by catatonic symptoms accompanied by autonomic instability, hyperthermia, and changes in laboratory values. In many cases, MC is not recognized as such. Evidence-based guidelines are essential to ensure quality of treatment, but what do current national and international guidelines recommend?

Method: Online search for international guidelines from English-, French-, Italian-, and German-speaking countries whose medical care meets high standards addressing the treatment of MC. These were analyzed and compared regarding statements on MC, recommendations, and strength of scientific evidence.

Results: Fifteen of the identified guidelines were included. Only 5 of 15 comment on the treatment of MC. As for other rare diseases, no detailed recommendations are available. Suggested therapies are limited to benzodiazepines and electroconvulsive therapy. Levels of evidence and grades of recommendation are predominantly low.

Conclusion: Many international guidelines do not mention MC. It is not possible to derive a clear algorithm for the treatment of MC from most current guidelines. A thorough update of most guidelines appears to be necessary. Lack of awareness and knowledge of MC among physicians and medical professionals might lead to inadequate or delayed care, worsened outcome, or death.

MeSH terms

  • Antipsychotic Agents / therapeutic use
  • Benzodiazepines / therapeutic use
  • Catatonia / therapy*
  • Electroconvulsive Therapy / methods
  • Global Health*
  • Humans
  • Practice Guidelines as Topic / standards*
  • Psychotherapy / methods
  • Rare Diseases

Substances

  • Antipsychotic Agents
  • Benzodiazepines